Related Experiment Video
Updated: May 8, 2026
15:53
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
PARP1-specific inhibitor displays PARP1-detrapping activity.
Kira Schützenhofer1, Ellen Laker1, Kyle Tsang1
1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.
Cell Reports
|May 6, 2026
Summary
PARP inhibitors trap PARP1/2 at DNA damage sites, but mutations affect trapping and drug response. This study reveals how specific PARP1 catalytic mutations impact trapping, ADP-ribosylation activity, and sensitivity to PARP inhibitors like saruparib.
Area of Science:
- Molecular Biology
- Cancer Research
- Drug Discovery
Background:
- PARP inhibitors are effective against homologous recombination-deficient tumors by inhibiting PARP1 and PARP2.
- PARP inhibitor efficacy depends on their ability to trap PARP enzymes at DNA damage sites.
- Variations in PARP inhibitor trapping ability influence their toxicity.
Purpose of the Study:
- To investigate the impact of PARP1 catalytic site mutations on its ADP-ribosylation activity, DNA damage trapping, and cellular response to PARP inhibitors.
- To develop an inducible complementation system for studying PARP1 variants.
Main Methods:
- Developed an inducible complementation system for expressing tagged PARP1 variants.
- Assessed ADP-ribosylation activity, PARP trapping, and cell survival of PARP1 mutant cell lines.
- Tested cell line sensitivity to various PARP inhibitors, including saruparib.
Main Results:
- Certain PARP1 catalytic mutants showed altered ADP-ribosylation activity and trapping.
- Saruparib, a PARP1-specific inhibitor, induced release of specific PARP1 catalytic mutants, leading to resistance.
- Identified a PARP1 mutant with intact mono(ADP-ribosyl)ation but lacking poly(ADP-ribosyl)ation, demonstrating mono(ADP-ribosyl)ation's role in PARP1 release.
Conclusions:
- PARP1 catalytic site mutations significantly influence PARP trapping and cellular response to PARP inhibitors.
- Mono(ADP-ribosyl)ation plays a crucial role in the release of PARP1 from DNA damage sites.
- Understanding these mechanisms can inform the development of more effective PARP inhibitor therapies.
Related Concept Videos
02:37Restarting Stalled Replication Forks
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart, a...
01:02Long-patch Base Excision Repair
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
02:36DNA Damage can Stall the Cell Cycle
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...